PTEN-AKT-FOXO3 Gene Expression Relation With Low-ovarian Reserve in Endometriomas
Study Details
Study Description
Brief Summary
In this study, we aimed to investigate the relationship between PTEN-AKT-FOXO3 gene expression and decrease in ovarian reserve in the presence of endometrioma and other benign ovarian pathologies.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
It is known that the presence of endometrioma negatively affects ovarian reserve. The development of endometriosis and the effect of the presence of endometrioma on ovarian reserve due to decreased PTEN expression are considered. This study was designed to compare ovarian PTEN-AKT-FOXO3 gene expression and ovarian reserve in patients with underwent surgery caused by endometrioma and those who had ovarian pathology due to other benign causes and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
PATİENCE GROUP To be in the range of 18-40 years Patients with an operation indication with >=5 cm endometrioma Symptomatic patients due to endometrioma (dysmenorrhea, dyspareunia, chronic pelvic pain, etc.) Patients who will be followed for IVF cycle due to infertility |
Genetic: PTEN-AKT-FOXO3 Gene Expression
In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
|
PATİENCE-CONTROL GROUP To be in the range of 18-40 years Patients with operation plan due to non-endometrioma ovarian pathologies Symptomatic patients with benign ovarian pathology (such as chronic pelvic pain, compression, syphilomas, dysmenorrhea, dyspareunia, etc.) Asymptomatic, despite a 6-month follow-up period, increase in cyst size or become symptomatic |
Genetic: PTEN-AKT-FOXO3 Gene Expression
In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
|
Outcome Measures
Primary Outcome Measures
- PTEN AKT FOXO3 gene expression [30 minutes]
In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
- To be in the range of 18-40 years 2) Patients with an operation indication with >=5 cm endometrioma 3) Patients with operation plan due to non-endometrioma ovarian pathologies
Exclusion Criteria:
- 1)Patients over the age of 40 2)Patients with suspected malignancy 3)Follow-up patients without indications for operation
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Uludag University Hospital, Department of Obstetrics and Gynecology | Bursa | Nilufer | Turkey | 16059 |
2 | Uludag University Hospital, Department of Obstetrics and Gynecology | Bursa | Nilufer | Turkey | 16059 |
Sponsors and Collaborators
- Uludag University
Investigators
- Study Director: GURKAN UNCU, Prof, ULUDAG UNIVERSITY HOSPITAL BURSA TURKEY
Study Documents (Full-Text)
None provided.More Information
Publications
- Govatati S, Kodati VL, Deenadayal M, Chakravarty B, Shivaji S, Bhanoori M. Mutations in the PTEN tumor gene and risk of endometriosis: a case-control study. Hum Reprod. 2014 Feb;29(2):324-36. doi: 10.1093/humrep/det387. Epub 2013 Oct 23.
- Kasapoglu I, Ata B, Uyaniklar O, Seyhan A, Orhan A, Yildiz Oguz S, Uncu G. Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study. Fertil Steril. 2018 Jul 1;110(1):122-127. doi: 10.1016/j.fertnstert.2018.03.015. Epub 2018 Jun 20.
- UU-MREC-2019-5/28